A5023939060- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Immune Cell Function and Interaction
- CAR-T cell therapy research
- Neuroendocrine Tumor Research Advances
- Colorectal Cancer Treatments and Studies
- Immunotherapy and Immune Responses
- Cancer Genomics and Diagnostics
- Sarcoidosis and Beryllium Toxicity Research
- Chronic Lymphocytic Leukemia Research
- Inflammatory Biomarkers in Disease Prognosis
- Cancer therapeutics and mechanisms
- Cardiac tumors and thrombi
- Immune cells in cancer
- Nonmelanoma Skin Cancer Studies
- Cutaneous lymphoproliferative disorders research
- Cancer and Skin Lesions
- Multiple and Secondary Primary Cancers
- Ocular Diseases and Behçet’s Syndrome
- Hereditary Neurological Disorders
- Peripheral Neuropathies and Disorders
- Global Cancer Incidence and Screening
- Vasculitis and related conditions
- Biosimilars and Bioanalytical Methods
Indiana University Health
2023-2025
Indiana University – Purdue University Indianapolis
2023-2025
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
2023-2025
Indiana Cancer Consortium
2023
University of South Florida
2021-2022
Moffitt Cancer Center
2020-2021
WinnMed
2018-2019
Mayo Clinic in Florida
2017-2019
Jacksonville College
2017-2019
Government of the United States of America
2019
The treatment paradigm for patients with advanced non–small cell lung cancer has substantially changed the discovery of immunotherapy. incorporation immunotherapy into algorithms resulted in better outcomes patients, fewer side effects compared classic chemotherapeutic agents. Multiple options are now available cancer, ranging from single-agent to quadruple therapy, which involves dual immune checkpoint inhibitor plus chemotherapy or anti–vascular endothelial growth factor drugs. This...
Anti-programmed cell death 1 (PD-1) antibodies have demonstrated improved overall survival (OS) and progression-free (PFS) in a subset of patients with metastatic or locally advanced non-small lung cancer (NSCLC). To date, no blood biomarkers been identified NSCLC to predict clinical outcomes treatment anti-PD-1 antibodies.We performed an analysis retrospectively registered data 157 treated at Mayo Clinic Florida Rochester. White count, absolute neutrophil count (ANC), lymphocyte (ALC), ANC...
Abstract With improving survivorship in chronic lymphocytic leukemia (CLL), the risk of second primary malignancies (SPMs) has not been systematically addressed. Differences for SPMs among CLL survivors from Surveillance, Epidemiology, and End Results (SEER) database (1973–2015) were compared to individual expected general population. In ~270,000 person-year follow-up, 6487 new diagnosed with a standardized incidence ratio (SIR) 1.2 (95% CI:1.17–1.23). The higher was both solid (SIR 1.15;...
Anti-PD1 therapy demonstrated impressive, prolonged responses in advanced cutaneous squamous cell carcinoma (CSCC). Therapy for ICI-refractory/ineligible disease remains unclear. We performed a retrospective analysis locally-advanced/metastatic CSCC using cetuximab across three cohorts: immediately after ICI failure (A), not following (B), or without prior (C). The primary endpoint was the overall response rate (ORR). Secondary endpoints included disease-control (DCR), progression-free...
Genomic mutations impact non-small cell lung cancer (NSCLC) biology. The influence of sex and age on the distribution these alterations is unclear. We analyzed circulating-tumor DNA from individuals with advanced NSCLC March 2018 to October 2020. EGFR, KRAS, ALK, ROS1, BRAF, NTRK, ERBB2, RET, MET, PIK3CA, STK11, TP53 were assessed. evaluated differences by (<70 ≥70) using Fisher’s exact test. Of 34,277 samples, 30,790 (89.83%) had a detectable mutation 19,923 (58.12%) an alteration...
"CLO25-074: Outcomes to Immune Checkpoint Inhibitors (ICIs) According Programmed Death-Ligand 1 (PD-L1) Levels in KRAS-, KEAP1-, STK11-Mutant Lung Squamous Cell Carcinoma (LSCC)" published on 28 Mar 2025 by National Comprehensive Cancer Network.
"HSR25-173: Impact of Social Determinants Health on Lung Cancer Screening and Small Cell Outcomes in a County Hospital" published 28 Mar 2025 by National Comprehensive Network.
Immune checkpoint inhibitors have changed the treatment paradigm for patients with cancer. Though a majority of tolerate treatment, some develop hematologic toxicities, including eosinophilia. Eosinophilia has been associated better responses in melanoma, but this not investigated non-small-cell lung We present case woman metastatic adenocarcinoma who developed asymptomatic hypereosinophilia after initiation nivolumab. Her eosinophil count temporarily decreased transiently stopping...
Hyperprogression and pseudoprogression are two atypical responses to immune checkpoint inhibitor therapy that affect therapeutic decisions prognosis. Identification of predictive biomarkers for either before or during treatment remains a huge unmet need in cancer immunotherapy. Many studies have looked at potential biomarkers, including clinical factors laboratory findings (e.g., peripheral blood counts, circulating tumor DNA, cytokine levels). The results these been inconsistent, possibly...
A 54-year-old man presented to the emergency department with acute left-sided chest pain and left upper quadrant abdominal pain. He had a significant history of squamous cell carcinoma lung previously treated right pneumonectomy who ; is currently receiving adjuvant chemotherapy cisplatin. Physical examination was remarkable for tachycardia, hypertension mild tenderness. CT angiography revealed an aortic mural thrombus in ascending aorta arch without dissection, aneurysm or tortuosity aorta....
e20599 Background: The anti-PD-1 antibodies nivolumab and pembrolizumab have demonstrated improved overall survival (OS) progression free (PFS) in a subset of patients with metastatic or locally advanced lung cancer (LC). To date, no blood biomarkers been identified to predict clinical outcome agents. Methods: A retrospective analysis 52 LC treated single institution was performed. White cell count (WBC), absolute neutrophil (ANC), lymphocyte (ALC), ratio (ANC/ALC), eosinophil (AEC),...
9102 Background: Gene CDKN2A, which encodes for p16INK4a/p14ARF is known to be important growth suppressor gene. CDKN2A gene alteration has been reported in non-small cell lung cancer (NSCLC). However, the demographic and clinical features of NSCLC with coexisting association immunotherapy biomarkers such as PD-L1 tumor mutation burden are unknown. Methods: Tumor next-generation sequencing data from 197 patients who diagnosed at Mayo Clinic FL retrospectively analyzed. Patients alterations...
9562 Background: Anti-PD1 (aPD1) monotherapy with cemiplimab-rwlc or pembrolizumab is now considered standard of care for first-line management advanced CSCC not amenable to surgery curative radiotherapy. Previously chemotherapy anti-EGFR agents were commonly used these patients albeit modest efficacy and limited duration response. In prospective evaluation, the overall response rate (ORR) cetuximab was 28% disease control (DCR) 69% at 6 weeks. The second-line treatment following primary...
Infiltrative cardiomyopathies include a variety of disorders that lead to myocardial thickening resulting in constellation clinical manifestations and eventually heart failure could be the first clue reach diagnosis. Among more described infiltrative diseases is amyloid cardiomyopathy. The disease usually presents with subtle, nonspecific symptoms. Herein, we illustrate case recurrent syncope as initial presenting symptom for systemic polyneuropathy cardiomyopathy cause syncope. article...